Joel Greenblatt's BIO Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 152,384 shares of Bio-Rad Laboratories, Inc. (BIO) worth $42.48 M, representing 0.13% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 39 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in BIO, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2014, adding 236,762 shares. Largest reduction occurred in Q2 2015, reducing 174,636 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Bio-Rad Laboratories (BIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bio-Rad Laboratories (BIO) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +35,366 | Add 30.22% | 152,384 | $278.75 |
| Q4 2025 | -7,608 | Reduce 6.10% | 117,018 | $302.99 |
| Q3 2025 | +36,763 | Add 41.84% | 124,626 | $280.39 |
| Q2 2025 | +59,397 | Add 208.66% | 87,863 | $241.32 |
| Q1 2025 | +6,517 | Add 29.69% | 28,466 | $243.56 |
| Q4 2024 | +3,805 | Add 20.97% | 21,949 | $328.51 |
| Q3 2024 | -10,552 | Reduce 36.77% | 18,144 | $334.58 |
| Q2 2024 | -4,690 | Reduce 14.05% | 28,696 | $273.11 |
| Q1 2024 | -4,028 | Reduce 10.77% | 33,386 | $345.87 |
| Q4 2023 | +14,743 | Add 65.03% | 37,414 | $322.89 |
| Q3 2023 | +17,891 | Add 374.29% | 22,671 | $358.45 |
| Q2 2023 | +1,957 | Add 69.32% | 4,780 | $379.12 |
| Q1 2023 | +768 | Add 37.37% | 2,823 | $479.02 |
| Q4 2022 | +144 | Add 7.54% | 2,055 | $420.49 |
| Q3 2022 | -1,465 | Reduce 43.39% | 1,911 | $417.06 |
| Q2 2022 | -3,236 | Reduce 48.94% | 3,376 | $494.96 |
| Q1 2022 | -1,035 | Reduce 13.53% | 6,612 | $563.22 |
| Q4 2021 | +6,125 | Add 402.43% | 7,647 | $755.59 |
| Q3 2021 | -1,269 | Reduce 45.47% | 1,522 | $745.73 |
| Q2 2021 | -3,233 | Reduce 53.67% | 2,791 | $644.21 |
| Q1 2021 | +4,376 | Add 265.53% | 6,024 | $571.22 |
| Q4 2020 | -620 | Reduce 27.34% | 1,648 | $583.13 |
| Q3 2020 | -12,613 | Reduce 84.76% | 2,268 | $515.43 |
| Q2 2020 | -3,189 | Reduce 17.65% | 14,881 | $451.52 |
| Q1 2020 | -1,947 | Reduce 9.73% | 18,070 | $350.58 |
| Q4 2019 | +1,498 | Add 8.09% | 20,017 | $370.04 |
| Q3 2019 | +11,411 | Add 160.54% | 18,519 | $332.74 |
| Q2 2019 | +4,731 | Add 199.03% | 7,108 | $312.61 |
| Q1 2019 | -5,026 | Reduce 67.89% | 2,377 | $305.85 |
| Q4 2018 | +401 | Add 5.73% | 7,403 | $232.20 |
| Q3 2018 | +7,002 | New Buy | 7,002 | $313.05 |
| Q2 2016 | -67,705 | Sold Out | 0 | $0.00 |
| Q1 2016 | -23,582 | Reduce 25.83% | 67,705 | $136.73 |
| Q4 2015 | -24,484 | Reduce 21.15% | 91,287 | $138.66 |
| Q3 2015 | -8,510 | Reduce 6.85% | 115,771 | $134.31 |
| Q2 2015 | -174,636 | Reduce 58.42% | 124,281 | $150.61 |
| Q1 2015 | +57,943 | Add 24.05% | 298,917 | $135.18 |
| Q4 2014 | +236,762 | Add 5621.13% | 240,974 | $120.56 |
| Q3 2014 | +4,212 | New Buy | 4,212 | $113.49 |
Joel Greenblatt's Bio-Rad Laboratories Investment FAQs
Joel Greenblatt first purchased Bio-Rad Laboratories, Inc. (BIO) in Q3 2014, acquiring 4,212 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Bio-Rad Laboratories, Inc. (BIO) for 39 quarters since Q3 2014.
Joel Greenblatt's largest addition to Bio-Rad Laboratories, Inc. (BIO) was in Q4 2014, adding 240,974 shares worth $29.05 M.
According to the latest 13F filing for Q1 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 152,384 shares of Bio-Rad Laboratories, Inc. (BIO), valued at approximately $42.48 M.
As of the Q1 2026 filing, Bio-Rad Laboratories, Inc. (BIO) represents approximately 0.13% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Bio-Rad Laboratories, Inc. (BIO) was 298,917 shares, as reported at the end of Q1 2015.